Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany
2024

Use of Targeted Cancer Drugs for Lung Cancer in Germany

Sample size: 7833 publication Evidence: moderate

Author Information

Author(s): Nikolaj Rischke, Josephine Kanbach, Ulrike Haug

Primary Institution: Leibniz Institute for Prevention Research and Epidemiology – BIPS

Hypothesis

What is the real-world utilization of targeted cancer drugs requiring molecular tumor diagnostics in lung cancer patients in Germany?

Conclusion

Only 5% of lung cancer patients diagnosed in 2016 in Germany received at least one targeted therapy, with higher rates in East Germany compared to West Germany.

Supporting Evidence

  • 5% of lung cancer patients diagnosed in 2016 received targeted therapy.
  • 62% of patients treated with targeted drugs were female.
  • Median overall survival after the first targeted therapy was 22 months.
  • 30.2% of all patients had at least one code for molecular tumor diagnostics.
  • Proportion of patients treated with targeted drugs was higher in East Germany (6.2%) than in West Germany (4.8%).

Takeaway

Out of every 20 lung cancer patients in Germany, only 1 got special drugs that help fight their cancer. More patients in East Germany got these drugs than in West Germany.

Methodology

The study analyzed claims data from the GePaRD database, identifying lung cancer patients diagnosed in 2016 and following them until 2019 to assess drug utilization.

Potential Biases

Potential underreporting of molecular diagnostics due to lack of specific coding in claims data.

Limitations

The study relies on claims data, which may lack detailed information on cancer staging and histology.

Participant Demographics

Mean age at diagnosis was 69 years, with 44.8% female and 71.7% diagnosed at an advanced stage.

Statistical Information

Confidence Interval

95% CI 4.5–5.5

Digital Object Identifier (DOI)

10.1002/cnr2.70060

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication